MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 885 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
JNK-IN-19
CAS:<p>JNK-IN-19 (Compound Q8) is an inhibitor of c-Jun N-terminal kinase, utilized for the treatment and/or prevention of injuries prior to, during, or following surgery.</p>Fórmula:C22H24F3N6Na2O6PCor e Forma:SolidPeso molecular:602.41(±)-Perillaldehyde
CAS:<p>(±)-Perillaldehyde exhibits antidepressant effects in mice with stress-induced depressive-like behavior by modulating the olfactory nervous system. Additionally, it demonstrates anti-inflammatory activity by activating JNK in RAW264.7 cells and suppressing the expression of TNF-α, with an IC50 value of 171.7 μM.</p>Fórmula:C10H14OCor e Forma:SolidPeso molecular:150.22Cot inhibitor-3
CAS:<p>Cot inhibitor-3 (Compound 33) is an effective and selective cancerosaka thyroid (COT) kinase inhibitor with an IC50 of 4 nM. It can be used to prevent limpness caused by inflammation.</p>Fórmula:C30H28N8OCor e Forma:SolidPeso molecular:516.60RIPK2-IN-6
CAS:<p>RIPK2-IN-6 (Compound 15a) is an inhibitor of RIPK that specifically targets the phosphorylation of RIPK2, thereby suppressing the NF-κB and MAPK signaling pathways. It has demonstrated anti-inflammatory and anti-fibrotic activities in a mouse model of colitis induced by Dextran sodium sulfate.</p>Fórmula:C26H21NO3Cor e Forma:SolidPeso molecular:395.45MEK1/2-IN-2
<p>MEK1/2-IN-2 is a potent, ATP-competitive MEK1/2 inhibitor that exhibits equal inhibitory effects on wild-type MEK1/2 and a group of MEK1/2 mutant cells.</p>Fórmula:C28H22ClFN6OCor e Forma:SolidPeso molecular:512.97HPK1-IN-16
CAS:<p>HPK1-IN-16, a potent HPK1 inhibitor, useful for cancer research and treatment.</p>Fórmula:C28H27FN4OCor e Forma:SolidPeso molecular:454.54BMS-214662
CAS:<p>BMS-214662 is a selective farnesyl transferase inhibitor with anti-tumor activity, used in research on pancreatic cancer, head and neck cancer, and lung cancer.</p>Fórmula:C25H23N5O2S2Pureza:99.58% - 99.58%Cor e Forma:SolidPeso molecular:489.61HPK1-IN-31
<p>HPK1-IN-31 inhibitor with an IC 50 value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunotherapy .</p>Fórmula:C30H33N7O3Cor e Forma:SolidPeso molecular:539.63AMG-548 dihydrochloride
<p>AMG-548 dihydrochloride, an oral p38α inhibitor (Ki: 0.5 nM), selectively targets p38β, γ, δ, inhibits TNFα (IC50: 3 nM), and suppresses Wnt signaling.</p>Fórmula:C29H29Cl2N5OCor e Forma:SolidPeso molecular:534.48Lambertellin
CAS:<p>Lambertellin, an effective antibiotic, acts as both a bactericide and fungicide. It exerts anti-inflammatory effects in LPS-stimulated RAW 264.7 macrophages by modulating the activation of MAPK and NF-κB signaling pathways.</p>Fórmula:C14H8O5Cor e Forma:SolidPeso molecular:256.21KRAS inhibitor-34
CAS:<p>KRAS inhibitor-34 (compound 27) is a KRAS inhibitor with an IC50 of 6.4 nM and is utilized in oncological research.</p>Fórmula:C43H41F3N6O3Cor e Forma:SolidPeso molecular:746.82JNK-IN-21
CAS:<p>JNK-IN-21 (Compound 62) is an inhibitor of JNK-1.</p>Fórmula:C19H16N2O2SCor e Forma:SolidPeso molecular:336.408ERK2 IN-1
CAS:<p>ERK2 IN-1 is a selective ERK2 inhibitor with an IC50 of 7 nM.</p>Fórmula:C36H34FN7O2SPureza:98%Cor e Forma:SolidPeso molecular:647.76K-Ras-IN-4
CAS:K-Ras-IN-4 (compound CP163) is an inhibitor of K-Ras.Fórmula:C31H28F4N6O3SCor e Forma:SolidPeso molecular:640.65HPK1-IN-30
CAS:<p>HPK1-IN-30 is a potent inhibitor of HPK1. HPK1-IN-30 has potential for cancer disease research.</p>Fórmula:C25H23FN6Cor e Forma:SolidPeso molecular:426.49ATX inhibitor 26
CAS:<p>ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. It effectively inhibits cell migration and collagen gel contraction. Additionally, ATX inhibitor 26 demonstrates significant antifibrotic activity, reducing collagen deposition in a Bleomycin (BLM)-induced pulmonary fibrosis model.</p>Fórmula:C18H19Cl2N7O3Cor e Forma:SolidPeso molecular:452.30VVD-699
CAS:<p>VVD-699 is a covalent inhibitor of RAS-PI3K. It forms a covalent bond with cysteine at position 242 within the RAS-binding domain of PI3Kp110α, thereby obstructing the ability of RAS to activate PI3K. VVD-699 is capable of inhibiting the growth of tumors with RAS mutations and HER2 overexpression. It is applicable in research related to RAS mutation-associated cancers, such as those involving H358 lung cancer cells, A549 cells, and FaDu cells.</p>Fórmula:C25H30ClFN2O6S2Cor e Forma:SolidPeso molecular:573.097KRAS G12C inhibitor 15
CAS:<p>KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor .</p>Fórmula:C25H21ClF2N4O3Pureza:98%Cor e Forma:SolidPeso molecular:498.91CK1δ-IN-9
CAS:<p>CK1δ-IN-9 (Compound 8) is an inhibitor of casein kinase 1 (CK1), specifically targeting CK1δ with an IC50 of 1.4 nM. The compound also inhibits p38α and p38β with IC50 values of 0.25 μM and 0.78 μM, respectively. CK1δ-IN-9 exhibits favorable pharmacokinetic properties, including high oral bioavailability (70%) and moderate clearance.</p>Fórmula:C16H12FN5Cor e Forma:SolidPeso molecular:293.298SHR2415
<p>SHR2415: Potent, selective ERK1/2 inhibitor, oral; ERK1 IC50: 2.8 nM, ERK2 IC50: 5.9 nM; effective in Colo205 (IC50: 44.6 nM), for cancer research.</p>Fórmula:C23H22ClN7O2Cor e Forma:SolidPeso molecular:463.92
